Testing a new insulin delivery method for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new way to give insulin directly into the abdomen (intraperitoneal) for people with type 1 diabetes. It will check how safe and effective a single dose is over 12 hours, using a special procedure to keep blood sugar stable (clamp).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have had type 1 diabetes for at least 12 months.
- You use an insulin pump or multiple daily injections (basal and bolus) and have been on a stable dose for at least 3 months.
- Your average blood sugar (HbA1c) is 8.5% or lower.
- Your body mass index (BMI) is between 18.5 and 30, and you weigh at least 50 kg.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new automated insulin delivery system to help people with type 1 diabetes better manage their blood sugar. It aims to see if the system improves glucose control safely.
This study tests a system that measures blood sugar and automatically adjusts insulin delivery. It is for adults with type 1 diabetes who use insulin injections or a pump.
This study tests a new hybrid closed-loop system (an automated insulin pump) in people with type 1 diabetes whose blood sugar is not well controlled. It aims to see if the system is safe and helps improve glucose levels.
This study compares a new automated insulin delivery algorithm (AIDANET) in two modes: fully closed-loop (no user input needed) versus hybrid closed-loop (user still gives some insulin for meals). It tests how well the algorithm works in real-life settings for adults with type 1 diabetes.
This study tests a smart insulin pump system that adjusts automatically during exercise. It aims to make managing blood sugar easier and safer.
This Phase 1 study tests an injectable HDV-insulin lispro to see how well it can reduce how much glucose your body makes on its own in people with type 1 diabetes. It is mainly focused on safety and finding the right dose range.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.